Vodobatinib is a third‐generation ABL1 kinase inhibitor and is in phase I/II stage for treatment‐refractory/intolerant CML (NCT02629692). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.